Plant · Scientific monograph
Senna alexandrina
Senna
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Digestive health, Gastrointestinal motility
Research overview
Historical use
Senna leaf has longstanding laxative use; EMA recognizes well-established short-term use for occasional constipation [4].
Modern research context
Senna preparations have been studied for constipation, with short-term symptom benefits and important electrolyte and obstruction precautions [1][4]. A 28-day randomized trial in 90 adults compared senna, magnesium oxide and placebo; improvement favored active groups [1]. Exact senna part and anthranoid standardization were not specified in its abstract, so no product-specific dose is given here. BMS Level B provisional for constipation; a favorable OTC systematic review uses a different grading system [2]. EMA limits unsupervised leaf-medicine use to one week; the research duration is not general-use guidance [4].
Adverse effects
Abdominal cramps, diarrhea and allergic reactions can occur. Prolonged use may disturb fluid/electrolyte balance and cause reversible intestinal pigmentation; incidence is not established here [4].
Contraindications
EMA contraindications include hypersensitivity, bowel obstruction/stenosis, atony, appendicitis, inflammatory bowel disease, unexplained abdominal pain, severe dehydration, pregnancy, lactation and age under 12. Persistent constipation or symptoms suggesting obstruction require medical assessment [4].
Clinical and phytochemical data
Used part
EMA profile concerns senna leaf. Pods have related but separately specified preparations. Constipation RCT abstract does not identify plant part or sennoside content [1][4].
Primary active compounds
Sennosides (hydroxyanthracene glycosides); preparations are standardized, but the RCT abstract omits content [1][4]
Mechanism of action
Colonic bacteria convert sennosides to rhein anthrone; anthranoid laxative action alters colonic motility and water/electrolyte transport. Mechanism does not justify chronic unrestricted use [4].
Pharmacokinetics
Absorption
Sennosides are not absorbed or split by human enzymes in the upper gut; some metabolites are absorbed after colonic activation [4].
Distribution
Whole-preparation distribution is incompletely defined. EMA describes a small human pod-powder PK study; pod findings are not identical to a leaf-product PK profile [4].
Metabolism
Bacterial conversion to rhein anthrone occurs in the colon; circulating metabolites include conjugates [4].
Excretion
EMA describes mainly fecal elimination with some urinary/biliary metabolite elimination; no universal leaf-extract half-life is established here [4].
Safety and interactions
Drug interactions
Potassium depletion during prolonged misuse can potentiate cardiac glycosides and interact with antiarrhythmics; diuretics, corticosteroids and liquorice may increase potassium loss [4]. EMA advises medical consultation with QT-prolonging medicines and these interacting drug classes [4].
Toxicity
Fluid/electrolyte depletion is a principal misuse risk. A case report linked chronic senna exposure with cholestatic hepatitis, with confounders and no incidence estimate [3][4].
Special precautions
Pregnancy
Contraindicated in the EMA senna-leaf monograph; experimental anthranoid findings underpin precaution [4].
Lactation
Contraindicated by EMA; small quantities of active metabolites can enter milk [4].
Hepatic impairment
Suspected liver injury has been reported; no validated hepatic dose adjustment identified [3][4].
Renal impairment
Kidney disorders increase concern about electrolyte disturbances; no validated renal dose adjustment identified [4].
Sources and references
- [1] - Morishita D, Tomita T, Mori S, Kimura T, Oshima T, Fukui H, Miwa H. Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. The American journal of gastroenterology 2021. PMID: 32969946. DOI: 10.14309/ajg.0000000000000942.
- [2] - Rao SSC, Brenner DM. Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review. The American journal of gastroenterology 2021. PMID: 33767108. DOI: 10.14309/ajg.0000000000001222.
- [3] - Sonmez A, Yilmaz MI, Mas R, Ozcan A, Celasun B, Dogru T, Taslipinar A, Kocar IH. Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation. Acta gastro-enterologica Belgica 2005. PMID: 16268429. DOI: Not reported.
- [4] - EMA/HMPC. Official herbal monograph, full regulatory text, sections 4.3–5.3. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-folium-revision-1_en.pdf Accessed 2026-10-25.